2025
Consensus guideline for the management of colorectal cancer with peritoneal metastases
Schultz K, Bansal V, Wach M, Bhutiani N, Godley F, Wang J, Waheed M, Buchheit J, Papai E, Campbell S, Schleimer L, Su D, Turaga K, Gunderson C, White M, Uppal A, Raghav K, Labow D, Sarpel U, Shergill A, Shen J, Eng C, Foote M, Baumgartner J, Group P. Consensus guideline for the management of colorectal cancer with peritoneal metastases. Cancer 2025, 131: e35869. PMID: 40558054, DOI: 10.1002/cncr.35869.Peer-Reviewed Original ResearchConceptsManagement of colorectal cancerCRC-PMColorectal cancerPeritoneal metastasisConsensus guidelinesPeritoneal surface malignancy centersCirculating tumor DNA testingUpfront cytoreductive surgerySite of metastasisProspective multicenter trialOptimal treatment strategyAssess agreement levelsLevel of evidenceOverall level of evidenceClinical management pathwaysModified Delphi techniqueCytoreductive surgerySystemic therapyMulticenter trialRisk stratificationTreatment strategiesPathway blockWeak recommendationPathological featuresMetastasisConsensus Guideline for the Management of Colorectal Cancer with Peritoneal Metastases
Schultz K, Bansal V, Wach M, Bhutiani N, Godley F, Waheed M, Buchheit J, Papai E, Campbell S, Schleimer L, Su D, Turaga K, Gunderson C, White M, Uppal A, Raghav K, Labow D, Sarpel U, Shergill A, Shen J, Eng C, Foote M, Baumgartner J. Consensus Guideline for the Management of Colorectal Cancer with Peritoneal Metastases. Annals Of Surgical Oncology 2025, 1-23. PMID: 40560497, DOI: 10.1245/s10434-025-17363-0.Peer-Reviewed Original ResearchManagement of colorectal cancerPeritoneal surface malignanciesCirculating tumor DNACRC-PMColorectal cancerPeritoneal metastasisConsensus guidelinesUpfront cytoreductive surgerySite of metastasisProspective multicenter trialOptimal treatment strategyAssess agreement levelsModified Delphi techniqueResultsThe overall levelClinical management pathwaysBackgroundThe peritoneumCytoreductive surgerySurface malignanciesSystemic therapyTumor DNAMulticenter trialRisk stratificationTreatment strategiesPathway blockWeak recommendationDiagnosis and management of cardiogenic shock.
Bellumkonda L. Diagnosis and management of cardiogenic shock. Current Opinion In Critical Care 2025 PMID: 40552838, DOI: 10.1097/mcc.0000000000001288.Peer-Reviewed Original ResearchCardiogenic shockLong-term outcomes of patientsOutcomes of patientsMultidisciplinary team-based approachLong-term outcomesManagement of cardiogenic shockAcute myocardial infarctionOverall prognosisStages of shockInfluence prognosisAggressive managementPoor prognosisRisk stratificationImprove mortalityTreatment strategiesTeam-based approachPhenotypic presentationMyocardial infarctionPrognosisClinical practiceEscalate careDisease processEarly identificationRefining interventionsPatientsAdvancing Precision Medicine in PDAC: An Ethical Scoping Review and Call to Action for IHC Implementation
Delgado-Coka L, Roa-Peña L, Flescher A, Escobar-Hoyos L, Shroyer K. Advancing Precision Medicine in PDAC: An Ethical Scoping Review and Call to Action for IHC Implementation. Cancers 2025, 17: 1899. PMID: 40563550, PMCID: PMC12191404, DOI: 10.3390/cancers17121899.Peer-Reviewed Original ResearchPancreatic ductal adenocarcinomaMolecular subtypesMolecular subtypes of pancreatic ductal adenocarcinomaSubtype of pancreatic ductal adenocarcinomaBasal-like tumorsMolecular subtyping methodsSystematic literature searchAnalysis of gene expressionPredictive biomarkersPreoperative settingAggressive subtypeGoogle Scholar databasesTherapy selectionDuctal adenocarcinomaLevel of transcriptionClinical managementTreatment strategiesGene expression profilesImmunohistochemistryBiomarker assessmentToxic treatmentMRNA analysisPrecision oncologyInclusion criteriaSubtyping methodsPrediction of Lymph Node Metastasis in Non–Small Cell Lung Carcinoma Using Primary Tumor Somatic Mutation Data
Lee V, Moore N, Doyle J, Hicks D, Oh P, Bodofsky S, Hossain S, Patel A, Aneja S, Homer R, Park H. Prediction of Lymph Node Metastasis in Non–Small Cell Lung Carcinoma Using Primary Tumor Somatic Mutation Data. JCO Clinical Cancer Informatics 2025, 9: e2400303. PMID: 40446175, DOI: 10.1200/cci-24-00303.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerLymph node metastasisArea under the receiver operating characteristic curveNode metastasisTreatment strategiesNon-small cell lung carcinomaPrediction of lymph node metastasisSurvival analysisSNP dataLymph node metastasis statusAssociated with lymph node metastasisCell lung carcinomaCell lung cancerLymph node metastasis predictionReceiver operating characteristic curveDiagnostic methodsPersonalized treatment strategiesSingle-nucleotide polymorphism (SNPChi-square testMedian AUCLung carcinomaClinical outcomesNon-smallRisk stratificationLogistic regression modelsTrial in progress: ENCORE—Multicenter prospective registry of sequential antibody drug conjugates (ADCs) in HER2 negative metastatic breast cancer (MBC) (TBCRC-067).
Huppert L, Ellisen L, Anders C, Isaacs C, Santa-Maria C, Anampa J, DeMichele A, Balic M, Specht J, Lustberg M, Wolff A, Krop I, Rugo H. Trial in progress: ENCORE—Multicenter prospective registry of sequential antibody drug conjugates (ADCs) in HER2 negative metastatic breast cancer (MBC) (TBCRC-067). Journal Of Clinical Oncology 2025, 43: tps1137-tps1137. DOI: 10.1200/jco.2025.43.16_suppl.tps1137.Peer-Reviewed Original ResearchMetastatic breast cancerReal-world overall survivalProgression free survivalHER2-negative metastatic breast cancerMetastatic triple negative breast cancerStandard of careAntibody-drug conjugatesDisease control rateDuration of responseOverall survivalBreast cancerPatient-reported outcomesFree survivalHER2 negative metastatic breast cancerTreatment strategiesHormone receptor-positive/HER2-negativeNegative metastatic breast cancerTriple negative breast cancerEffective new treatment strategyPhase III clinical trialsRegistry study of patientsKaplan-Meier methodNegative breast cancerIII clinical trialsNew treatment strategiesLeveraging Alzheimer’s Disease Omics to Identify Pleiotropic Genes Contributing to Neurodegeneration in Primary Open-Angle Glaucoma
Tolosa-Tort P, DeWan A. Leveraging Alzheimer’s Disease Omics to Identify Pleiotropic Genes Contributing to Neurodegeneration in Primary Open-Angle Glaucoma. Molecular Neurobiology 2025, 1-10. PMID: 40411683, DOI: 10.1007/s12035-025-05074-2.Peer-Reviewed Original ResearchPrimary open-angle glaucomaOpen-angle glaucomaOpen-angle glaucoma riskPrimary open-angle glaucoma riskIntraocular pressure controlGene expressionGenome-wide association studiesAlzheimer's diseasePOAG riskGlaucoma riskIrreversible blindnessCurrent therapiesGlaucomaTreatment strategiesMultivariate analysisPathogenic mechanismsEvidence of pleiotropyPressure controlNeuronal repairPrioritized genesBrain cortexAssociation studiesEarly detectionNeuroprotective pathwaysDiseaseInterventional treatment strategies for arteriovenous malformations of the mandible and maxilla: 30-year institutional case series.
Sujijantarat N, Padmanaban V, Larson A, Troulis M, Kaban L, Curtin H, Rabinov J. Interventional treatment strategies for arteriovenous malformations of the mandible and maxilla: 30-year institutional case series. Interventional Neuroradiology 2025, 15910199251343000. PMID: 40398476, PMCID: PMC12095211, DOI: 10.1177/15910199251343000.Peer-Reviewed Original ResearchArteriovenous malformationsFollow-up angiographyDental extractionTreatment strategiesAV shuntsConsecutive series of patientsHigh-flow arteriovenous malformationsHistory of hemorrhageInstitutional case seriesTime of biopsyRisk of hemorrhageOutcomes of patientsSeries of patientsEvaluate treatment strategiesArteriovenous (AVInterventional treatment strategiesConclusionsMultidisciplinary treatmentFocused surgeryRefractory bleedingResultsNine patientsAngiographic closureBleeding episodesAlveolar ridgeSpontaneous regressionTrans-arterialImmunological mechanisms and emerging therapeutic targets in alcohol-associated liver disease
Shen H, Liangpunsakul S, Iwakiri Y, Szabo G, Wang H. Immunological mechanisms and emerging therapeutic targets in alcohol-associated liver disease. Cellular & Molecular Immunology 2025, 1-15. PMID: 40399593, DOI: 10.1038/s41423-025-01291-w.Peer-Reviewed Original ResearchAlcohol-associated liver diseaseTherapeutic targetLiver diseaseOptimal treatment strategyAnti-inflammatory therapyNon-parenchymal liver cellsExtra-hepatic organsImprove patient outcomesImmune cellsImmunological mechanismsInflammatory cellsImmunological pathwaysTreatment strategiesInflammatory mediatorsDisease onsetGlobal health challengePatient outcomesNervous systemInflammationAdipose tissueLiver cellsPrecision medicineClinical researchDiseaseHealth challengesPatients with status epilepticus and new‐onset refractory status epilepticus display drastically altered fecal microbiomes compared to chronic epilepsy patients
Steriade C, Thomas S, Xu F, Ahituv A, Hanin A, Pleshkevich M, Hwang S, Ramirez A, Foreman B, Yoo J, Eka O, Kellogg M, Oliger A, Wainwright M, Morales M, Gaspard N, Hirsch L, Devinsky O, Saxena D. Patients with status epilepticus and new‐onset refractory status epilepticus display drastically altered fecal microbiomes compared to chronic epilepsy patients. Epilepsia 2025 PMID: 40387216, DOI: 10.1111/epi.18450.Peer-Reviewed Original ResearchChronic epilepsy patientsSE patientsStatus epilepticusEpilepsy patientsChronic epilepsyPre-existing epilepsyFuture treatment strategiesDisease time pointsInflammatory cytokine levelsFecal microbiomeMicrobiome structureLongitudinal cohort studyMicrobiome featuresCytokine levelsEffective therapyCohort studyTreatment strategiesInflammatory cytokinesSE resolutionInflammatory responseCritical illnessPatientsGut dysbiosisMortality rateClinical treatmentPharmacological and behavioral pain treatment strategies for patients with opioid use disorder
Ameral V, Hickey T, Reilly E, Patterson J, Sofuoglu M. Pharmacological and behavioral pain treatment strategies for patients with opioid use disorder. Expert Opinion On Pharmacotherapy 2025, 26: 1041-1054. PMID: 40366730, PMCID: PMC12202159, DOI: 10.1080/14656566.2025.2506688.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentOpioid use disorderChronic painUse disorderCochrane Central Register of Controlled TrialsCentral Register of Controlled TrialsEffective management of painPain treatment strategiesRegister of Controlled TrialsManagement of painCochrane Central RegisterAgonist treatmentPharmacological optionsTreatment strategiesPainOpioidEffective treatmentControlled trialsBehavioral treatmentTreatmentPatientsDisordersMedical careEffective managementEffective medical careA flexible Bayesian g-formula for causal survival analyses with time-dependent confounding
Chen X, Hu L, Li F. A flexible Bayesian g-formula for causal survival analyses with time-dependent confounding. Lifetime Data Analysis 2025, 31: 394-421. PMID: 40227517, DOI: 10.1007/s10985-025-09652-3.Peer-Reviewed Original ResearchConceptsG-formulaBalance scoresHealth system electronic health recordDiscrete survival dataTime-to-event outcomesPosterior sampling algorithmParametric g-formulaElectronic health recordsBayesian additive regression treesTime-varying treatmentsHypothetical intervention scenariosAdditive regression treesLongitudinal observational studyGeneral classModel misspecificationHealth recordsEmpirical performanceSampling algorithmObservational studySurvival dataIntervention scenariosScoresTreatment strategiesMisspecificationCausality analysisHER2 testing: evolution and update for a companion diagnostic assay
Robbins C, Bates K, Rimm D. HER2 testing: evolution and update for a companion diagnostic assay. Nature Reviews Clinical Oncology 2025, 22: 408-423. PMID: 40195456, DOI: 10.1038/s41571-025-01016-y.Peer-Reviewed Original ResearchConceptsHER2-targeted therapyHER2 testingHER2-lowSolid tumorsHER2-targeting antibody-drug conjugateHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Accuracy of HER2 testingHER2-low expressionHER2-low tumorsLevels of HER2 expressionTherapeutic decision-makingFluorescence in situ hybridizationAntibody-drug conjugatesTrastuzumab deruxtecanHER2 expressionImprove patient outcomesRNA-based assaysPatient selectionLow levels of HER2 expressionTumor typesBreast cancerQuantitative immunofluorescenceReceptor 2Treatment strategiesPredicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning
Bai Z, Osman M, Brendel M, Tangen C, Flaig T, Thompson I, Plets M, Scott Lucia M, Theodorescu D, Gustafson D, Daneshmand S, Meeks J, Choi W, Dinney C, Elemento O, Lerner S, McConkey D, Faltas B, Wang F. Predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning. Npj Digital Medicine 2025, 8: 174. PMID: 40121304, PMCID: PMC11929913, DOI: 10.1038/s41746-025-01560-y.Peer-Reviewed Original ResearchMuscle-invasive bladder cancerResponse to neoadjuvant chemotherapyNeoadjuvant chemotherapyBladder cancerPredicting response to neoadjuvant chemotherapyOptimal treatment strategyImprove patient survivalImproving clinical outcomesGene expression profilesBladder preservationPredictive biomarkersPatient survivalUnnecessary treatmentClinical outcomesTreatment responseRNA sequencingTumor heterogeneityTreatment strategiesClinical trialsGene signatureExpression profilesMolecular determinantsCancerChemotherapyBuilding accurate predictive modelsLipid Peroxidation and Glutathione Levels Among People Living With HIV Co‐infected With Human Coronaviruses in Ghana
Amegashie E, Kwayisi‐Darkwah C, Adusei‐Poku M, Sikeola R, Ativi L, Ahene A, Atampugbire G, Tagoe E, Paintsil E, Torpey K, Quaye O. Lipid Peroxidation and Glutathione Levels Among People Living With HIV Co‐infected With Human Coronaviruses in Ghana. Journal Of Medical Virology 2025, 97: e70301. PMID: 40110873, DOI: 10.1002/jmv.70301.Peer-Reviewed Original ResearchMeSH KeywordsAdultCoinfectionCoronavirus InfectionsCross-Sectional StudiesCyclopropanesDideoxyadenosineDideoxynucleosidesFemaleGhanaGlutathioneHeterocyclic Compounds, 3-RingHIV InfectionsHumansLipid PeroxidationMaleMalondialdehydeMiddle AgedOxazinesOxidative StressPiperazinesProspective StudiesPyridonesYoung AdultConceptsHuman immunodeficiency virusHuman immunodeficiency virus co-infectionCo-infectionGSH levelsART-experienced individualsPLWH co-infectedHuman coronavirusesHIV co-infectionHIV-negative individualsMalondialdehyde levelsOxidative stressOxidative stress markersIncreased MDA levelsCross-sectional studyOro-pharyngeal swabsImmunodeficiency virusGhanaian patientsMono-infectionReduced GSH levelsTreatment strategiesPlasma samplesDisease severityMDA levelsStress markersTailored monitoringLeveraging space innovations for cancer breakthroughs on Earth
Akbarialiabad H, Jamshidi P, Aminzade Z, Azizi N, Taha S, Sadeghian N, Varghese L, Kouhanjani M, Niknam N, Babocs D, El-Assaad F, Russomano T, Murrell D, Paydar S, Bunick C, Christiansen R, Melin M. Leveraging space innovations for cancer breakthroughs on Earth. Trends In Cancer 2025, 11: 433-440. PMID: 40082142, DOI: 10.1016/j.trecan.2025.02.003.Peer-Reviewed Original ResearchConceptsTumor microenvironmentRefine treatment strategiesImproving cancer diagnosticsCancer cell behaviorInduce profound alterationsTumor biologyTreatment strategiesImmune responseCancer progressionCancer therapeuticsCancer breakthroughsCancerCancer biologyTumorCancer diagnosticsEnhance drug discoveryTherapeuticsMicrogravity-induced changesImmune dysregulation in glycogen storage disease 1b extends beyond neutropenia
Gehlhaar A, Shouval D, Santiago E, Ling G, McCourt B, Werner L, Yerushalmi B, Konnikova L. Immune dysregulation in glycogen storage disease 1b extends beyond neutropenia. Human Immunology 2025, 86: 111268. PMID: 40037121, DOI: 10.1016/j.humimm.2025.111268.Peer-Reviewed Original ResearchGlycogen storage disease type 1bGlycogen storage disease type 1b patientsImpaired immune cell traffickingClassic treatment strategiesUpregulation of CXCR3Effector memory phenotypeT cell populationsNatural killer cellsSystems immunology approachNon-classical monocytesImmune cell traffickingGlycogen storage disease 1bImmune defectsMemory phenotypeMultiple T cell populationsImmune landscapeRecurrent infectionsKiller cellsImmune dysregulationImmune impairmentImmunophenotypic characterizationSLC37A4 geneControl subjectsTreatment strategiesNeutrophil numbersChronic chemotherapy-induced peripheral neuropathy: living with neuropathy during and after cancer treatments
Rahman N, Sukumar J, Lustberg M. Chronic chemotherapy-induced peripheral neuropathy: living with neuropathy during and after cancer treatments. Annals Of Palliative Medicine 2025, 14: 19616-19216. PMID: 40211744, DOI: 10.21037/apm-24-154.Peer-Reviewed Original ResearchConceptsQuality of lifeChemotherapy-induced peripheral neuropathyFunctional statusPrevalence of chemotherapy-induced peripheral neuropathyImpact of chemotherapy-induced peripheral neuropathyTreatment strategiesAssociated with riskPatients experience symptomsCancer survivorsCurrent treatment strategiesPatient experiencePeripheral nerve damageDebilitating side effectsPrevention strategiesSymptoms of sadnessDose adjustmentPsychological impactClinical presentationClinical factorsNerve damagePeripheral neuropathyChemotherapeutic agentsSymptomatic reliefRisk factorsDiagnostic evaluationCold and hot fibrosis define clinically distinct cardiac pathologies
Miyara S, Adler M, Umansky K, Häußler D, Bassat E, Divinsky Y, Elkahal J, Kain D, Lendengolts D, Flores R, Bueno-Levy H, Golani O, Shalit T, Gershovits M, Weizman E, Genzelinakh A, Kimchi D, Shakked A, Zhang L, Wang J, Baehr A, Petrover Z, Sarig R, Dorn T, Moretti A, Saez-Rodriguez J, Kupatt C, Tanaka E, Medzhitov R, Krüger A, Mayo A, Alon U, Tzahor E. Cold and hot fibrosis define clinically distinct cardiac pathologies. Cell Systems 2025, 16: 101198. PMID: 39970910, PMCID: PMC11922821, DOI: 10.1016/j.cels.2025.101198.Peer-Reviewed Original ResearchConceptsHeart failureMyocardial infarctionAutocrine growth factor loopsUnmet medical needCardiac fibrosisNeutralizing antibodiesReduced fibrosisTreatment strategiesMyofibroblast proliferationAcute MIFibrosis post-MICardiac pathologyFibrosisTherapeutic approachesPost-MIChronic injuryMyofibroblastsMedical needFactor loopsThe REpeated ASSEssment of SurvivorS in intracerebral haemorrhage: protocol for a multicentre, prospective observational study
Ziai W, Woo D, Sansing L, Hanley D, Ostapkovich N, Triene K, Gilkerson L, Thompson R, Walborn N, Lane K, McBee N, Langefeld C, Howard T, Vagal A, Flaherty M, Consortium F. The REpeated ASSEssment of SurvivorS in intracerebral haemorrhage: protocol for a multicentre, prospective observational study. BMJ Open 2025, 15: e094322. PMID: 39915023, PMCID: PMC11800296, DOI: 10.1136/bmjopen-2024-094322.Peer-Reviewed Original ResearchConceptsMinimally invasive surgeryIntracerebral haemorrhageInvasive surgeryNon-surgical standard of careProspective observational studySpontaneous intracerebral haemorrhageStandard of careRepeated assessmentsCognitive declineICH volumeInstitutional review boardHaematoma volumeMISTIE IIITreated patientsInflammatory stateTreatment strategiesEthnic/Racial VariationsRt-PAAssessment of survivorsObservational studyRate of cognitive declineUniversity Institutional Review BoardHaemorrhageReview boardPeer-reviewed journals
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply